Sanofi Income After Taxes 2010-2024 | SNY
Sanofi annual/quarterly income after taxes history and growth rate from 2010 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
- Sanofi income after taxes for the quarter ending December 31, 2024 was $0.442B, a 193.09% decline year-over-year.
- Sanofi income after taxes for the twelve months ending December 31, 2024 was $5.945B, a 1.05% decline year-over-year.
- Sanofi annual income after taxes for 2024 was $5.945B, a 1.05% decline from 2023.
- Sanofi annual income after taxes for 2023 was $6.008B, a 32.25% decline from 2022.
- Sanofi annual income after taxes for 2022 was $8.867B, a 20.11% increase from 2021.
Sanofi Annual Income After Taxes
(Millions of US $) |
| 2024 |
$5,945 |
| 2023 |
$6,008 |
| 2022 |
$8,867 |
| 2021 |
$7,383 |
| 2020 |
$13,697 |
| 2019 |
$3,005 |
| 2018 |
$4,634 |
| 2017 |
$4,304 |
| 2016 |
$4,816 |
| 2015 |
$5,035 |
| 2014 |
$6,062 |
| 2013 |
$5,101 |
| 2012 |
$6,100 |
| 2011 |
$6,775 |
| 2010 |
$5,786 |
| 2009 |
$6,557 |
Sanofi Quarterly Income After Taxes
(Millions of US $) |
| 2024-12-31 |
$442 |
| 2024-09-30 |
$3,041 |
| 2024-06-30 |
$1,177 |
| 2024-03-31 |
$1,284 |
| 2023-12-31 |
$-475 |
| 2023-09-30 |
$2,692 |
| 2023-06-30 |
$1,648 |
| 2023-03-31 |
$2,144 |
| 2022-12-31 |
$3,282 |
| 2022-09-30 |
$2,087 |
| 2022-06-30 |
$1,269 |
| 2022-03-31 |
$2,230 |
| 2021-09-30 |
$2,769 |
| 2021-06-30 |
|
| 2021-03-31 |
$1,892 |
| 2020-09-30 |
$2,289 |
| 2020-03-31 |
$1,696 |
| 2019-09-30 |
$1,984 |
| 2019-03-31 |
$1,249 |
| 2018-03-31 |
$1,249 |
| 2017-12-31 |
$21 |
| 2017-09-30 |
$1,750 |
| 2017-06-30 |
$1,145 |
| 2017-03-31 |
$1,388 |
| 2016-12-31 |
$809 |
| 2016-09-30 |
$1,883 |
| 2016-06-30 |
$1,109 |
| 2016-03-31 |
$1,015 |
| 2015-09-30 |
$1,756 |
| 2015-06-30 |
$1,509 |
| 2014-06-30 |
$1,100 |
| 2013-06-30 |
$646 |
| 2012-06-30 |
$1,421 |
| 2012-03-31 |
$2,086 |
| 2011-12-31 |
$1,682 |
| 2011-09-30 |
$2,570 |
| 2011-06-30 |
$1,141 |
| 2011-03-31 |
$1,382 |
| 2010-12-31 |
$356 |
| 2010-09-30 |
$1,578 |
| 2010-06-30 |
$1,839 |
| 2010-03-31 |
$2,013 |
| 2009-12-31 |
$1,902 |
| 2009-09-30 |
$1,792 |
| 2009-06-30 |
$1,260 |
| 2009-03-31 |
$1,604 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$140.749B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
